ライフサイエンスコーパス: PPSV23

1 PPSV23 uptake varies substantially by age and indication

2 PPSV23-unique types increased in adults 19-64 years with

3 PPSV23-unique types increased in adults 19-64 years with

4 ompared to mock immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16.83; P = 0.0467

5 h pneumolysin toxoid (psiPLY), Pneumovax 23 (PPSV23; Merck, Whitehouse Station, NJ), or phosphate-buf

6 cal polysaccharide vaccine (Pneumovax(R) 23; PPSV23) or PLY protects against pneumococcal endophthalm

7 Adding PPSV23 at age 75 years to PCV13 at ages 50 and 65 years

8 ed serotypes after PCV13 and to 6 additional PPSV23 serotypes in participants aged >=60 years; seroty

9 R range, 3.00-6.97), and little change after PPSV23 (GMFR range, 0.86-1.12).

10 after PCV13 and 7 additional serotypes after PPSV23 in participants aged >=60 years; noninferiority w

11 Co-administering COVID-19, Influenza, and PPSV23 vaccines seems feasible, without significantly im

12 Vitreous of PLY (2.88 MPO untis/mL) and PPSV23/PLY (2.17) passively immunized rabbits had less M

13 eading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis)

14 res of serum antibodies induced by PCV13 and PPSV23 at 1 month and 1 year.

15 t pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for asplenic i

16 Both PCV20 and PPSV23 vaccines were evaluated for protection against ci

17 8.20% of patients from the PCV13/PPSV23 and PPSV23 groups, respectively, reached the primary end poi

18 cted corneas were higher for the psiPLY- and PPSV23-immunized rabbits after infection with WU2, when

19 previous observational studies and to assess PPSV23 vaccine effectiveness in preventing IPD and the m

20 ealth Interview Survey, the authors assessed PPSV23 uptake in people with established and new indicat

21 tent controls who received PCV13 followed by PPSV23 2 months later.

22 munogenicity of PCV13 at week 0, followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 i

23 ssed the immunogenicity of PCV13 followed by PPSV23 in IBD patients by measuring serotype-specific pn

24 al vaccination schedule of PCV13 followed by PPSV23 is safe, immunogenic, and thus beneficial in the

25 In these cases, PPSV23 as currently recommended was favored.

26 lin G (IgG) and functional antibody than did PPSV23 1 month after vaccination.

27 s 18-64 years of age (18.6%) had established PPSV23 indications; adding asthma and smoking to the lis

28 Disease Control and Prevention criteria for PPSV23 administration, almost 50% of individuals had nev

29 Vaccine effectiveness for PPSV23 was assessed using multivariable conditional logi

30 % of people with established indications for PPSV23 and 17.4% of people with any indication (those pr

31 ic medical conditions (CMCs, indications for PPSV23 use alone), and 74% (95% CI, -78% to -70%) in adu

32 nic medical conditions (CMC, indications for PPSV23 use alone), and 74% (95%CI:-78,-70) in adults wit

33 rette smoking to the list of indications for PPSV23 vaccination.

34 administration of PCV13 as a substitute for PPSV23 in current recommendations (ie, vaccination at ag

35 ions (PLY = 31.34% loss of retinal function, PPSV23/PLY = 27.44%) helped to significantly preserve re

36 ical severity compared to mock immunization (PPSV23 = 9.19, PPSV23/PLY = 10.45, PLY = 8.71, Mock = 16

37 s were more common in the COVID-19+Influenza+PPSV23 group (adjusted OR: 2.04, p < 0.001), though no s

38 , COVID-19+Influenza, and COVID-19+Influenza+PPSV23 groups, respectively.

39 or COVID-19+Influenza and COVID-19+Influenza+PPSV23, respectively.

40 had previously received 1 or >/= 2 doses of PPSV23.

41 al disease, but the lack of effectiveness of PPSV23 in protecting against all-cause HTP should be con

42 with antiserum to PLY, PPSV23, a mixture of PPSV23/PLY, or PBS (mock).

43 to serotypes shared with PCV15 (cohort 1) or PPSV23 (cohort 2), and higher immune responses to seroty

44 tered the combination immunization (5.29) or PPSV23 (5.29) with vancomycin treatment compared to cont

45 e randomized in the PCV13/PPSV23 (n = 63) or PPSV23-alone groups (n = 65).

46 mmunogenicity comparable to that of PCV13 or PPSV23.

47 V13 and PPSV23 (Guillain-Barre syndrome), or PPSV23 (cellulitis).

48 3 and were randomized 2:1 to receive V116 or PPSV23, respectively; cohort 3 (n = 106) previously rece

49 previously received PPSV23 + PCV13, PCV13 + PPSV23, PCV15 + PPSV23, or PCV15 and all received open-l

50 2007-2008, by age and serotype group (PCV13, PPSV23-unique, or nonvaccine types [NVTs]), among adults

51 2007-2008, by age and serotype group (PCV13, PPSV23-unique, or types in neither vaccine [NVT]), among

52 A PCV13/PPSV23 regimen improved the breadth and magnitude of ant

53 A combined PCV13/PPSV23 strategy improved the breadth of responses to 0-1

54 l, 128 patients were randomized in the PCV13/PPSV23 (n = 63) or PPSV23-alone groups (n = 65).

55 24.56% and 8.20% of patients from the PCV13/PPSV23 and PPSV23 groups, respectively, reached the prim

56 iters were significantly higher in the PCV13/PPSV23 than in the PPSV23-alone group for 5 serotypes (4

57 titer ratio (ratio of PCV20/saline to PCV13/PPSV23 group) was >0.5.

58 ived PPSV23 + PCV13, PCV13 + PPSV23, PCV15 + PPSV23, or PCV15 and all received open-label V116.

59 d serotypes, but for none (0/7) of the PCV20/PPSV23-shared serotypes.

60 e 13 serotypes common to V116 and PCV15 plus PPSV23 and for the eight serotypes unique to V116.

61 erally similar to those seen with PCV15 plus PPSV23 at week 12 for the 13 common serotypes and higher

62 plus placebo group and 157 in the PCV15 plus PPSV23 group) and 304 (97%) completed part A (152 in eac

63 of 155 vs 141 [91%] of 155 in the PCV15 plus PPSV23 group) with a lower frequency of injection-site a

64 e passively immunized with antiserum to PLY, PPSV23, a mixture of PPSV23/PLY, or PBS (mock).

65 COVID-19 mRNA, Influenza, and Pneumococcal (PPSV23) vaccines in adults.

66 dified by reduction, and both polysaccharide PPSV23 and conjugate PCV20 vaccines contain 12F Ags with

67 sion levels of a distinct gene set predicted PPSV23 responses.

68 ividuals with beta-thalassemia, but previous PPSV23s affect the memory B-cell response in a dose- and

69 Prior PPSV23 receipt was not associated with protection agains

70 responses in HIV-infected adults with prior PPSV23 vaccination and CD4 cell counts >/= 200 cells/mm(

71 te to severe COPD were randomized to receive PPSV23 (n = 90) or PCV7 (1.0 mL; n = 91).

72 vely; cohort 3 (n = 106) previously received PPSV23 + PCV13, PCV13 + PPSV23, PCV15 + PPSV23, or PCV15

73 tors independently associated with receiving PPSV23, they used multivariable logistic regression and

74 ost-effective than the currently recommended PPSV23 strategy.

75 a greater functional antibody response than PPSV23 in patients with COPD that persists for 2 years a

76 The PPSV23 vaccine is effective against the most severe inva

77 d 24.6% versus 52.5%, 31%, 8%, and 8% in the PPSV23 group.

78 antly higher in the PCV13/PPSV23 than in the PPSV23-alone group for 5 serotypes (4, 14, 19A, 19F, 23F

79 Relative to PPSV23, PCV7 induced greater OPK at both 1 and 2 years f

80 The capsular polysaccharide vaccine PPSV23 and conjugated alternative PCV13 can prevent thes

81 e in current use: the polysaccharide vaccine PPSV23 and the glycoconjugate vaccine PCV13.

82 -valent pneumococcal polysaccharide vaccine (PPSV23) 1 month later.

83 -valent pneumococcal polysaccharide vaccine (PPSV23) 2 months later is recommended.

84 -valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later.

85 -valent pneumococcal polysaccharide vaccine (PPSV23) among US adults is unclear.

86 -valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent PCV within specified geographic an

87 -valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4 cell counts >/= 200 cells/mm(3) and

88 -valent pneumococcal polysaccharide vaccine (PPSV23) and were randomized 2:1 to receive V116 or PCV15

89 -valent pneumococcal polysaccharide vaccine (PPSV23) for nonelderly adults with certain medical condi

90 -valent pneumococcal polysaccharide vaccine (PPSV23) for preventing all-cause pneumonia still undeter

91 s with the 23-valent polysaccharide vaccine (PPSV23) in 2012.

92 s with the 23-valent polysaccharide vaccine (PPSV23) in 2012.

93 lowed by a 23-valent polysaccharide vaccine (PPSV23) is poorly documented in adults with SCD.

94 -valent pneumococcal polysaccharide vaccine (PPSV23) protects against invasive disease in young healt

95 -valent pneumococcal polysaccharide vaccine (PPSV23) remains unclear among immunocompromised patients

96 saline or 23-valent polysaccharide vaccine (PPSV23).

97 -valent pneumococcal polysaccharide vaccine [PPSV23]).

98 insurance were independently associated with PPSV23 receipt.

99 followed by PPSV23 at week 4, compared with PPSV23 alone at week 4 in adult patients with SCD.

100 PCV13 vaccination was favored compared with PPSV23, but the analysis was sensitive to assumptions ab

101 In comparison with PPSV23, PCV13 induced higher titers across antibody isot

102 </= 0.0010), whereas rabbits immunized with PPSV23 and Freund's adjuvant failed to show differences

103 ntisera from rabbits actively immunized with PPSV23 and Freund's adjuvant were nonopsonizing.

104 nized with PBS and Freund's adjuvant or with PPSV23 and Freund's adjuvant at 48 hours after infection

105 vaccinated 39 older adults (>60 years) with PPSV23 or PCV13 and observed comparable antibody respons

106 d with an influenza vaccine, with or without PPSV23 from January to December 2022.